Alpha 2.0
Login Register
» Authors » Stephen Strugnell

Stephen Strugnell

Explore the profile of Stephen Strugnell including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 83
Followers 0
Related Specialties
Biochemistry
Nephrology
Molecular Biology
Top 10 Co-Authors
Charles W Bishop
Joyce C Knutson
Valarie Byford
Glenville Jones
Akhtar Ashfaq
Hugh L J Makin
Sonoko Masuda
Martin Kaufmann
Dilip K Deb
Yurong Wang
Published In
J Steroid Biochem Mol Biol
Biochim Biophys Acta
Am J Physiol Renal Physiol
BMC Nephrol
Anticancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism
Merante D, Schou H, Morin I, Manu M, Ashfaq A, Bishop C, et al.
Nephron . 2024 Apr; 148(10):657-666. PMID: 38657576
Background: Early secondary hyperparathyroidism (SHPT) diagnosis and treatment are crucial to delay the progression of SHPT and related complications, in particular, cardiovascular events and bone fractures. Extended-release calcifediol (ERC) has...
2.
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
Germain M, Paul S, Fadda G, Broumand V, Nguyen A, McGarvey N, et al.
BMC Nephrol . 2022 Nov; 23(1):362. PMID: 36368937
Introduction: Extended-release calcifediol (ERC), active vitamin D hormones and analogs (AVD) and nutritional vitamin D (NVD) are commonly used therapies for treating secondary hyperparathyroidism (SHPT) in adults with stage 3-4...
3.
Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation
Petkovich M, Melnick J, White J, Tabash S, Strugnell S, Bishop C
J Steroid Biochem Mol Biol . 2014 Dec; 148:283-9. PMID: 25446887
Vitamin D insufficiency is prevalent in chronic kidney disease (CKD) and associated with secondary hyperparathyroidism (SHPT) and increased risk of bone and vascular disease. Unfortunately, supplementation of stage 3 or...
4.
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist
Zhang Y, Deb D, Kong J, Ning G, Wang Y, Li G, et al.
Am J Physiol Renal Physiol . 2009 Jun; 297(3):F791-801. PMID: 19535571
The intrarenal renin-angiotensin system (RAS) plays a key role in the development of diabetic nephropathy. Recently, we showed that combination therapy with an AT(1) receptor blocker (ARB) and an activated...
5.
Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs
Jones G, Byford V, West S, Masuda S, Ibrahim G, Kaufmann M, et al.
Anticancer Res . 2006 Aug; 26(4A):2589-95. PMID: 16886668
Like most pharmaceutical agents, vitamin D analogs are subject to hepatic metabolism by a variety of cytochrome P450 (CYP)-based systems. Metabolism can involve activation as well as inactivation of the...
6.
Insights into Vitamin D metabolism using cyp24 over-expression and knockout systems in conjunction with liquid chromatography/mass spectrometry (LC/MS)
Masuda S, Kaufmann M, Byford V, Gao M, St-Arnaud R, Arabian A, et al.
J Steroid Biochem Mol Biol . 2004 Jul; 89-90(1-5):149-53. PMID: 15225763
The development of novel gene expression systems for cytochrome P450s (CYPs) together with a revolution in analytical mass spectrometry with the emergence of liquid chromatography/mass spectrometry (LC/MS) has opened the...
7.
Use of vitamin D(4) analogs to investigate differences in hepatic and target cell metabolism of vitamins D(2) and D(3)
Byford V, Strugnell S, Coldwell R, Schroeder N, Makin H, Knutson J, et al.
Biochim Biophys Acta . 2002 Jul; 1583(2):151-66. PMID: 12117559
In this study, we used molecules with either of the structural differences in the side chains of vitamin D(2) and vitamin D(3) to investigate which feature is responsible for the...